Asia-Pacific Cannabidiol Market Overview

Asia Pacific Cannabidiol Market Trends

The Asia Pacific cannabidiol market size was estimated at USD 440.5 million in 2023 and is projected to grow at a remarkable compound annual growth rate (CAGR) of 24.1% from 2024 to 2030. This rapid growth is a direct reflection of the increasing acceptance and legalization of hemp-based products, heightened awareness of cannabidiol’s potential health benefits, and a saturation of products infused with cannabidiol across various categories.

To meet ever-evolving consumer demands, companies are embracing innovation by expanding their product lines to include edibles, topicals, and beverages infused with CBD. The buoyant growth of e-commerce platforms significantly amplifies their reach, enabling market players to tap into a larger customer base and boost sales, thus positively influencing growth forecasts in this burgeoning industry.

The Asia Pacific region stands as the third-largest CBD market globally, selling cannabidiol in various forms, including capsules, edibles, hemp oil, and vaping e-liquid. Noteworthy companies like Eos Scientific, operating under the banner of Ambiance Cosmetics, are home to a diverse range of six CBD-infused cosmetic lines, which showcase oils, balms, and moisturizers. As more individuals uncover the potential health benefits of CBD, investment in research and development intensifies, paving the way for new products and amplifying market competitiveness.

However, it’s worth noting that the CBD landscape in Asia presents a unique challenge. Unlike Western markets, which promote medical and recreational usage of cannabis, many Asian nations face strict regulations regarding cannabis-based products. Countries like Indonesia enforce notably rigid drug laws, imposing severe penalties, including life imprisonment and hefty fines, for those involved with illegal drugs, including cannabis. As a result, the medical cannabis market in these regions is hindered, with few countries acknowledging even the medical use of CBD. For instance, India remains ambivalent about regulatory decisions related to CBD products, compelling patients to rely on imported CBD medicines, often at steep costs due to restrictive permissions.

Market Concentration & Characteristics

The Asia Pacific CBD market is solidly positioned in a high growth phase, expected to continue this trajectory through 2030. The rising acceptance of CBD oils and products among the youth population—especially for health and wellness—plays a pivotal role in this expansion.

As research capabilities blossom across the region, there’s a concentrated push toward understanding CBD’s potential applications. Companies are embracing innovation, resulting in an influx of products—ranging from beverages to skincare and even pet treats. This demand surge translates into a market populated by diverse offerings, including CBD oil, concentrates, isolators, and more.

Furthermore, the rapid growth of consumer awareness concerning CBD’s health benefits—especially its potential to alleviate anxiety, pain, sleep disorders, and skin issues—has led to an increased appetite for expansion. Companies like Hemp Naturals, based in Australia, have successfully launched a variety of CBD products catering to both local and international markets.

Interestingly, while some Asian countries maintain stringent restrictions on CBD, China emerges as a significant player, being the largest hemp cultivator in the region. With nearly half of the world’s hemp production, China also exports about 90% of its products to countries like the U.S., Germany, and Japan. Partnerships have become common as companies seek regional expansion; for example, CV Sciences, a U.S.-based firm, teamed up with Health Science Holdings to distribute its PlusCBD oil in Thailand.

Source Type Insights

In 2023, hemp-derived CBD dominated the CBD oil market with a revenue share of 77.2%. Given the increasing demand from the pharmaceutical sector and rising awareness of health benefits, this segment is anticipated to grow rapidly. The legitimization of cannabis for medical uses and a rise in consumer purchasing power are expected to further propel the demand for CBD in pharmaceuticals. Popular products include oils, tinctures, concentrates, and a selection of edibles like baked goods, coffee, chocolate, gum, and candies.

Hemp-derived CBD is gaining traction, attributed to its anti-inflammatory, anti-aging, and antioxidant properties. A wide array of sectors, from pharmaceuticals to personal care, are now formulating products fortified with CBD, which is expected to drive significant growth in this sector.

End-use Insights

In the B2B segment, pharmaceuticals commanded the largest revenue share of 64.7% in 2023, a trend expected to strengthen over the forecast period. This spike can be linked to the increasing number of clinical trials investigating CBD’s efficacy across various health conditions. Companies are purchasing CBD oil in bulk for product infusions, often sought by consumers to manage pain and stress, indicating robust market growth.

The transition of CBD from a mere herbal remedy to a prescribed medication is contributing to market expansion. As pharmaceutical entities recognize the medical benefits and therapeutic potential of CBD, demand within this sector is set to accelerate.

Sales Type Insights

The B2B segment continues to dominate, claiming a 64.7% revenue share in 2023. This segment is poised for rapid growth, driven by the influx of CBD oil wholesalers and the burgeoning demand for CBD as a raw ingredient. As regulatory landscapes become more accommodating, opportunities for distribution are opening up, further amplifying market expansion.

The hospital pharmacies sub-segment within B2C is anticipated to see noteworthy growth in the coming years, fueled by strategic partnerships between CBD companies and retail pharmacies. This growth will foster a better-presenced market for CBD products, catering to a growing number of patients opting for this treatment option.

Country Insights

China Cannabidiol Market Trends

The cannabidiol market in China accounted for the largest revenue share of 47.7% in 2023 in Asia Pacific. The country is a leading player, exporting nearly 90% of its products globally while currently permitting the sale of hemp oil and using CBD in cosmetics. However, the market remains restricted to four licensed companies, which limits community access. Nevertheless, as the sector flourishes, the number of cultivators and producers is anticipated to rise, further propelling demand for CBD extracts like oil, edibles, and tinctures.

Australia Cannabidiol Market Trends

The Australian cannabidiol market is set for the fastest growth projected at a CAGR of 34.1% from 2024 to 2030. Since the legalization of medical cannabis in 2016, Australia has seen a remarkable uptick in patients obtaining prescriptions for cannabis and derived products. The market is witnessing an influx of companies as well, with many being listed on the Australian Stock Exchange. Heightened interest has led local businesses to pursue cultivation licenses, attracting investments from established players.

India Cannabidiol Market Trends

India’s cannabidiol market is also expected to register a lucrative CAGR from 2024 to 2030. The rising incorporation of CBD in cosmetic products has ushered in a revolution within the country’s cosmetics industry. Additionally, initiatives like the February 2023 workshop organized by Awshad—a Delhi-NCR-based cannabis wellness startup—aim to educate healthcare professionals on the myriad applications of CBD, fostering a deeper understanding of medical cannabis in the region.

Key Cannabidiol Company Insights

Leading cannabidiol companies are strategically focusing on a variety of initiatives, including distribution partnerships and product innovations, to maintain market relevance. For instance, in October 2022, Charlotte’s Web Holdings, Inc. entered a distribution agreement with Gopuff Retail Company. Such collaborations enhance operational capabilities, broaden product ranges, and optimize overall competencies.

Recent Developments

• In April 2023, Aurora Cannabis, Inc. and MedReleaf Australia collaborated to launch IndiMed Tempo 26, a new line of dried cannabis products designed for medical patients under the MedReleaf Concession Scheme (MCS).

• In February 2023, Awshad, organized a medical cannabis workshop in New Delhi aimed at educating healthcare professionals about the applications and benefits of CBD.

• In June 2022, CHARLOTTE’S WEB signed a distribution agreement with Energy Hemp Biotechnology Ltd., granting exclusive rights for distribution of its CBD products in Greater China.

• In March 2021, Tilray obtained approvals from New Zealand’s health ministry for the commercialization of medicinal cannabis products in the market.

Asia Pacific Cannabidiol Market Report Scope

Asia Pacific Cannabidiol Market Report Segmentation

This report forecasts revenue growth at regional and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the Asia Pacific cannabidiol market report based on source type, sales type, end-use, and region:

• Source Type Outlook (Revenue, USD Million, 2018 – 2030­)
• Sales Type Outlook (Revenue, USD Million, 2018 – 2030­)
  • B2B
  • B2C
  • By Sales Channel
  • Hospital Pharmacies
  • Online
  • Retail Stores
  • By End-use
  • Medical
  • Chronic Pain
  • Mental Disorders
  • Cancer
  • Others
  • Personal Use
  • End-use Outlook (Revenue, USD Million, 2018 – 2030­)
  • Medical
  • Chronic Pain
  • Mental Disorders
  • Cancer
  • Others
  • Personal Use
  • Pharmaceuticals
  • Wellness
  • Country Outlook (Revenue, USD Million, 2018 – 2030­)
  • Asia Pacific
  • China
  • India
  • South Korea
  • New Zealand
  • Japan
  • Australia